Back to search

Article

The Alzheimers Association Global Biomarker Standardization Consortium (GBSC) plasma phospho-tau Round Robin study

2024-08-22

Abstract excerpt

BACKGROUND: Phosphorylated tau (p-tau) is a specific blood biomarker for Alzheimers disease (AD) pathology. Multiple p-tau biomarkers on several analytical platforms are poised for clinical use. The Alzheimers Association Global Biomarker Standardisation Consortium plasma phospho-tau Round Robin study engaged assay developers in a blinded case-control study on plasma p-tau, aiming to learn which assays provide the...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
2db10507-da43-5bd8-9a31-3b693e9bf223
DOI
10.1101/2024.08.22.24312244
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
The Alzheimers Association Global Biomarker Standardization Consortium (GBSC) plasma phospho-tau Round Robin studyDOI 10.1101/2024.08.22.24312244
A Comprehensive Head-to-Head Comparison of Key Plasma Phosphorylated Tau 217 Biomarker TestsSemantic proximity
Multi-Platform Comparison of Plasma Phosphorylated Tau Assays: Analytical and Workflow Factors Drive Clinical Implementation DecisionsSemantic proximity
Pittsburgh plasma p-tau217: classification accuracies for autosomal dominant and sporadic Alzheimer’s disease in the communitySemantic proximity
Robustness of plasma p-Tau217 diagnostic thresholds for Alzheimer’s disease across various clinical populations and laboratory environmentsSemantic proximity
CNS-selective plasma p-tau217 accurately captures Alzheimer’s disease pathology and progressionSemantic proximity
Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders.Semantic proximity
Analytical and Clinical Validation of a High Accuracy Fully Automated Digital Immunoassay for Plasma Phospho-Tau 217 for Clinical Use in Detecting Amyloid PathologySemantic proximity
Development and clinical validation of blood-based multibiomarker models for the evaluation of brain amyloid pathologySemantic proximity
High-sensitivity plasma proteomics reveals disease-specific signatures and predictive biomarkers of Alzheimer’s disease phenotypes in a large mixed dementia cohortSemantic proximity
Multi-cohort cerebrospinal fluid proteomics identifies robust molecular signatures across the Alzheimer disease continuumSemantic proximity
Progress regarding the context-of-use of tau as biomarker of Alzheimer’s disease and other neurodegenerative diseasesSemantic proximity
Plasma vs. serum: which is better for proteomic blood biomarker analysis? Evaluation of the novel NULISA platformSemantic proximity
Select a neighboring publication to make it the new centre.